Liver health in psoriatic arthritis with different treatments
Part of Bones, joints & muscles, Digestive system, Skin clinical trials.
This study compares liver health (including liver ultrasound and blood test results) in people with psoriatic arthritis who have been treated with different biologic medicines or methotrexate for at least 2 years. The goal is to see if one treatment may be more protective for the liver than others.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are between 18 and 65 years old.
- You have a confirmed diagnosis of psoriatic arthritis (a condition causing joint pain and skin psoriasis).
- You have been treated for at least 2 years with either a biologic medicine (anti-TNF or anti-IL-17) or methotrexate alone.
- You do not have any other liver disease (like hepatitis B or C, or autoimmune hepatitis).
- You do not drink more than a moderate amount of alcohol (about 1–2 drinks per day or less).
- You are willing to share your medical records related to liver ultrasounds and blood tests.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study uses a special ultrasound (like a painless scan) and a blood test to check for liver damage in people taking methotrexate. The goal is to find early signs of liver scarring so it can be managed sooner.
This trial tests if a treatment can prevent joint damage in people recently diagnosed with psoriatic arthritis. It compares a standard medication (methotrexate) with or without a newer biologic drug (adalimumab) to see which is better at stopping the disease from causing lasting harm.
This trial tests an experimental drug called FT2109 for people with psoriatic arthritis, a condition that causes joint pain, swelling, and skin psoriasis. The study aims to see if FT2109 can reduce symptoms and improve quality of life.
This study follows people with a first episode of peripheral (hand/foot/arm/leg) arthritis that seems to be psoriatic arthritis. It aims to improve understanding of early disease and may help guide more personalized care over time.
This trial tests a new drug, LPX-TI641, to see if it is safe and how it works in the body for people with rheumatoid arthritis or psoriatic arthritis. It may be an option if you have active joint swelling and pain despite standard treatments.
This study tests if adding a GLP-1 medication (a type of drug that helps with weight and blood sugar) to your usual psoriatic arthritis treatment can improve your joint and skin symptoms. It is for people with psoriatic arthritis who have not yet achieved good control of their disease and have a higher body weight.
Hear when a new Psoriatic Arthritis (PsA) trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.